Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NP 137

Next Previous
Search
Drug Profile

NP 137

Alternative Names: Anti-netrin-1; NP-137; NP137P; NP137R

Latest Information Update: 27 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Netris Pharma
  • Developer Centre Leon Berard; Merck Sharp & Dohme; Netris Pharma; University Hospital Grenoble
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Acute myeloid leukaemia; Cervical cancer; Endometrial cancer
  • Phase I Liver cancer; Pancreatic cancer
  • Preclinical Endometriosis

Most Recent Events

  • 27 Feb 2025 Preclinical trials in Endometriosis in France (IV) prior to February 2025 (Netris Pharma pipeline, February 2025)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV, Injection)
  • 12 Jan 2024 NETRIS Pharma plans a phase I trial for Pancreatic cancer (First-line therapy, Neoadjuvant therapy, Combination therapy) in the US (IV) (NCT06203821)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top